AU2019393784B2 - Compounds for the treatment of arenavirus infection - Google Patents

Compounds for the treatment of arenavirus infection Download PDF

Info

Publication number
AU2019393784B2
AU2019393784B2 AU2019393784A AU2019393784A AU2019393784B2 AU 2019393784 B2 AU2019393784 B2 AU 2019393784B2 AU 2019393784 A AU2019393784 A AU 2019393784A AU 2019393784 A AU2019393784 A AU 2019393784A AU 2019393784 B2 AU2019393784 B2 AU 2019393784B2
Authority
AU
Australia
Prior art keywords
compound
independently selected
alkyl
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019393784A
Other languages
English (en)
Other versions
AU2019393784A1 (en
Inventor
Eric Brown
Vidyasagar Reddy Gantla
Gregory Henkel
Kenneth Mccormack
Michael Bruno Plewe
Nadezda Sokolova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arisan Therapeutics Inc
Original Assignee
Arisan Therapeutics Inc
Arisan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arisan Therapeutics Inc, Arisan Therapeutics Inc filed Critical Arisan Therapeutics Inc
Publication of AU2019393784A1 publication Critical patent/AU2019393784A1/en
Application granted granted Critical
Publication of AU2019393784B2 publication Critical patent/AU2019393784B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019393784A 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection Active AU2019393784B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
US62/776,390 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (2)

Publication Number Publication Date
AU2019393784A1 AU2019393784A1 (en) 2021-05-27
AU2019393784B2 true AU2019393784B2 (en) 2025-06-12

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019393784A Active AU2019393784B2 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Country Status (9)

Country Link
EP (1) EP3890731A4 (cg-RX-API-DMAC7.html)
JP (1) JP7675009B2 (cg-RX-API-DMAC7.html)
CN (1) CN113329750B (cg-RX-API-DMAC7.html)
AR (1) AR117228A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019393784B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010909A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191001A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021005234A (cg-RX-API-DMAC7.html)
WO (1) WO2020117794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217490B (zh) * 2023-02-03 2025-09-26 中国人民解放军军事科学院军事医学研究院 一种苯并咪唑类化合物及其制备方法和应用
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
AU2024409086A1 (en) * 2023-12-20 2026-08-06 Arisan Therapeutics Inc. Crystalline forms of an imidazopyridine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
MX359989B (es) * 2012-02-17 2018-10-18 Siga Tech Inc Fármacos antivirales para el tratamiento de la infección por arenavirus.
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Also Published As

Publication number Publication date
JP2022509763A (ja) 2022-01-24
JP7675009B2 (ja) 2025-05-12
MX2021005234A (es) 2021-08-11
KR20210106997A (ko) 2021-08-31
AU2019393784A1 (en) 2021-05-27
BR112021010909A2 (pt) 2021-08-24
CN113329750A (zh) 2021-08-31
WO2020117794A1 (en) 2020-06-11
EP3890731A4 (en) 2022-08-17
MX2024013042A (es) 2024-12-06
EA202191001A1 (ru) 2021-08-16
CA3118765A1 (en) 2020-06-11
AR117228A1 (es) 2021-07-21
EP3890731A1 (en) 2021-10-13
CN113329750B (zh) 2025-10-17

Similar Documents

Publication Publication Date Title
US11352328B2 (en) Heterocyclic compounds for the treatment of arenavirus
AU2018331172B2 (en) Influenza virus replication inhibitor and use thereof
US11548893B2 (en) Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
US12240857B2 (en) Adamantane derivatives for the treatment of filovirus infection
CN114057702B (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
CN109415367A (zh) 用于治疗和预防乙型肝炎病毒感染的新的二氢吡咯并嘧啶类化合物
BR112014007134B1 (pt) Usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso do composto para fabricação de um medicamento para tratar ou prevenir infecções flavivirais
JP6859358B2 (ja) テトラヒドロインダゾール及びその医学的使用
US12358897B2 (en) Compounds and method of treating COVID-19
EP3544961B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7675009B2 (ja) アレナウイルス感染症の治療のための化合物
WO2022266368A1 (en) Protease inhibitors and methods of use
US20210244721A1 (en) Small molecule enterovirus inhibitors and uses thereof
US12419865B2 (en) Compounds for the treatment of arenavirus infection
CA3118765C (en) Compounds for the treatment of arenavirus infection
CN105873924B (zh) 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
OA20266A (cg-RX-API-DMAC7.html)
EA044865B1 (ru) Соединения для лечения аренавирусной инфекции
WO2021262426A9 (en) Adamantane amides and thioamides for the treatment of ebolavirus infection
JPH09301976A (ja) 2−アリール−5,11−ジヒドロ−6H−ジピリド[3,2−b:2′,3′−e][1,4]ジアゼピン及びHIV感染の治療におけるその使用
HK40014598A (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
HK40014598B (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)